Drug Shortage Bill In House Refines Hatch Reimbursement Proposal
Sterile injectable products with three or fewer manufacturers would get better federal reimbursement rates in an effort to attract more producers to the market; H.R. 6611 was modeled after a similar proposal from Sen. Orrin Hatch, R-Utah.
You may also be interested in...
Even as agency touts its progress and expands its powers, it acknowledges the limits of notification.
OGD Director Geba says generic manufacturers still suffer from extensive quality problems, but GPhA officials argue the industry is doing fine and communications with the agency need to be more uniform.
Advocates for the agency worry that while each of the performance assessments seems reasonable individually, together the reports could burden staff to the point of pulling some from application reviews or other tasks to help complete them.